PD-L1 Expression in Mastocytosis
AbstractProgrammed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against the PD-1/PD-L1 interaction have gained clinical importance. PD-L1 expression has been assessed in a few studies on mastocytosis. We review this literature and the need for further investigation of the tumor-immune interaction in mastocytosis. View Full-Text
Share & Cite This Article
Williams, M.; Lidke, D.S.; Hartmann, K.; George, T.I. PD-L1 Expression in Mastocytosis. Int. J. Mol. Sci. 2019, 20, 2362.
Williams M, Lidke DS, Hartmann K, George TI. PD-L1 Expression in Mastocytosis. International Journal of Molecular Sciences. 2019; 20(9):2362.Chicago/Turabian Style
Williams, Margaret; Lidke, Diane S.; Hartmann, Karin; George, Tracy I. 2019. "PD-L1 Expression in Mastocytosis." Int. J. Mol. Sci. 20, no. 9: 2362.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.